Exencial Wealth Advisors LLC Has $2.83 Million Stake in Sanofi (NASDAQ:SNY)

Exencial Wealth Advisors LLC decreased its position in shares of Sanofi (NASDAQ:SNY) by 0.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 58,711 shares of the company’s stock after selling 203 shares during the period. Exencial Wealth Advisors LLC’s holdings in Sanofi were worth $2,832,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Synergy Asset Management LLC acquired a new position in shares of Sanofi during the fourth quarter valued at about $25,000. McClarren Financial Advisors Inc. raised its position in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after buying an additional 543 shares during the last quarter. Sunbelt Securities Inc. raised its position in shares of Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after buying an additional 313 shares during the last quarter. Sierra Ocean LLC acquired a new position in shares of Sanofi during the fourth quarter valued at about $44,000. Finally, Versant Capital Management Inc acquired a new position in shares of Sanofi during the fourth quarter valued at about $54,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Stock Performance

NASDAQ SNY opened at $57.70 on Wednesday. The stock has a market cap of $146.43 billion, a P/E ratio of 23.17, a PEG ratio of 1.01 and a beta of 0.57. The company’s 50-day simple moving average is $52.00 and its 200 day simple moving average is $52.64. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on SNY. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi has an average rating of “Buy” and an average price target of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.